Core Insights - Douglas Lane & Associates has increased its investment in Thermo Fisher Scientific by purchasing 16,745 shares valued at approximately $7.79 million, bringing its total holdings to 216,276 shares [2][11] - Following this purchase, Thermo Fisher Scientific accounts for 1.5% of the fund's reportable assets under management as of September 30, 2025 [3] Company Overview - Thermo Fisher Scientific reported a total revenue of $43.21 billion and a net income of $6.58 billion for the trailing twelve months [4] - The company has a dividend yield of 0.32% and its stock price was $534.68 as of October 9, 2025, reflecting a 12% decline over the past year [3][4] Business Performance - Thermo Fisher achieved a 3% revenue growth to $10.9 billion in its fiscal second quarter, with a 6% year-over-year increase in diluted earnings per share (EPS) to $4.28 [13] - The company has raised its fiscal guidance for 2025 to approximately $44 billion in sales, up from $42.9 billion the previous year [14] Investment Rationale - The current price-to-earnings (P/E) ratio of Thermo Fisher is lower than it was a year ago, suggesting that the stock is more attractively valued now [12] - The combination of rising revenue, increasing EPS, and a reasonable P/E ratio positions Thermo Fisher stock as a compelling buy opportunity [14]

Core Insights - Labcorp Holdings Inc. is valued at a market cap of $23 billion and is a leading global provider of comprehensive laboratory services [1] - The company operates through its Diagnostics Laboratories and Biopharma Laboratory Services segments, offering a wide range of testing, specialty diagnostics, and drug development solutions [1][2] Financial Performance - Labcorp's shares have fallen 2.7% from its 52-week high of $283.47 but have risen 5.4% over the past three months, outperforming The Health Care Select Sector SPDR Fund's (XLV) 2.6% gain [3] - Year-to-date, Labcorp's stock is up 20.3%, significantly exceeding XLV's 1.1% decline, and has soared 24.2% over the past 52 weeks compared to XLV's 12.4% decrease [4] - The company reported strong Q2 2025 results with adjusted EPS of $4.35 and revenues of $3.53 billion, surpassing estimates [5] - Growth in Q2 was driven by Diagnostics Laboratories, which grew 8.9% to $2.75 billion, and Biopharma Laboratory Services, which rose 11% to $784.8 million [5] - Full-year 2025 guidance has been raised, with revenue growth now expected at 7.5% - 8.6% and adjusted EPS at $16.05 - $16.50 [5] Market Position and Analyst Sentiment - Despite rival Quest Diagnostics Incorporated (DGX) outperforming Labcorp on a year-to-date basis with a 22.4% increase, Labcorp has outperformed DGX over the past 52 weeks [6] - Analysts maintain a bullish outlook on Labcorp, with a consensus rating of "Strong Buy" from 18 analysts and a mean price target of $295.53, representing a 5.9% premium to current levels [6]

Core Insights - Labcorp, a global leader in laboratory services, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025 [1] - A live audio webcast of the event will be available on the Company Investor Relations website and archived for later replay [1] Company Overview - Labcorp provides innovative and comprehensive laboratory services to assist doctors, hospitals, pharmaceutical companies, researchers, and patients in making informed decisions [2] - The company employs nearly 70,000 individuals and serves clients in approximately 100 countries [2] - Labcorp supported over 75% of new drugs and therapeutic products approved by the FDA in 2024 and conducts more than 700 million tests annually [2]